Chinese healthcare firms to raise $2 billion in HK IPOs

China NT Pharma and Shanghai Pharmaceuticals aim to raise as much as $2 billion in Hong Kong IPOs this month.
They might hurt, but the increasing popularity of vaccines in China is good news for NT Pharma
They might hurt, but the increasing popularity of vaccines in China is good news for NT Pharma

Hong Kong investors are preparing for an influx of healthcare equities that could absorb $2 billion of capital in the coming weeks as two Chinese pharmaceutical companies roll out plans for initial public offerings.

Shanghai Pharmaceuticals, which is already listed in its home city, said last month that shareholders had approved the company’s H-share offering plan and that the China Securities Regulatory Commission had accepted its listing application. Last week, the company raised its original $1.2 billion target to between $1.5 billion and $1.8 billion, and said that it aims to list in Hong Kong by the end of this month.

On the same day, Shanghai Pharmaceuticals’...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222